Repligen Conference: CEO touts differentiated bioprocessing portfolio; CFO targets 30% EBITDA margin
Repligen (NASDAQ:RGEN) executives outlined a strategy focused on portfolio breadth, innovation, and commercial execution during a recent discussion with Life Science Analyst Paul Knight. Chief Executi ...
Congratulations) Join me on a solo bushcraft adventure as I build a dugout shelter in the mountains. Watch as I use my ...
From freeing up capital to cutting down on housework and clutter, Eleanor Mills reveals why she has no regrets about swapping her grand abode for smaller square footage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results